Form 4: Ionis Pharmaceuticals Executive Trades Common Stock

Joseph Baroldi, EVP and Chief Business Officer at Ionis Pharmaceuticals, reported transactions involving the acquisition and disposition of company stock.

Summary

• Joseph Baroldi, EVP, Chief Business Officer of Ionis Pharmaceuticals, engaged in stock transactions on June 26, 2026.
• He acquired 3,866 shares of common stock at $56.78 per share and an additional 1,769 shares at $32.60 per share.
• Concurrently, 5,635 shares were disposed of at a weighted average price of $80.1595, with individual sales ranging from $80.00 to $80.52.
• These dispositions were made pursuant to a Rule 10b5-1 Trading Plan adopted by his spouse.
• Following these transactions, Baroldi beneficially owns 4,669 shares directly and 48,522 shares indirectly through his spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports routine insider transactions under a pre-arranged plan, with both acquisitions and dispositions occurring.

Positives

• Acquisition of 3,866 shares at $56.78 and 1,769 shares at $32.60 suggests a belief in the stock's value at these price points.
• The existence of a Rule 10b5-1 trading plan indicates pre-planned, systematic trading activity, often viewed positively for its transparency and adherence to compliance.
• A significant portion of shares (48,522) remain beneficially owned indirectly through his spouse, indicating continued long-term commitment.

Negatives

• The sale of 5,635 shares at prices significantly higher than the acquisition prices ($80.1595 average sale price vs. $56.78 and $32.60 acquisition prices) could be interpreted as profit-taking.
• The total number of shares disposed of (5,635) is substantial relative to the number of shares acquired in these specific transactions.

Risks

• The sale of shares under a Rule 10b5-1 plan, while compliant, can sometimes be perceived by the market as an indication of an executive's intention to reduce their holdings.
• The weighted average sale price of $80.1595 for 5,635 shares indicates a significant disposition of equity.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by an executive at a biopharmaceutical company like Ionis Pharmaceuticals is common for managing personal stock sales in a compliant manner, especially given the often volatile nature of biotech stock prices.

Stakeholder Impact

• Shareholders: The sale of shares by an executive may be interpreted by some shareholders as a signal, though the Rule 10b5-1 plan mitigates this by indicating a pre-determined strategy.
• Employees: The transactions do not directly impact employees but reflect executive compensation and stock ownership practices.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continued monitoring of Joseph Baroldi's beneficial ownership and any future transactions.
• Observation of Ionis Pharmaceuticals' stock performance and corporate developments.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Stock Transaction, Insider Trading, Rule 10b5-1, Joseph Baroldi, Executive Officer, Beneficial Ownership, Stock Sale, Stock Acquisition